tbuckley/cabot-search huggingface dataset:
P-89 Validation of the prognostic significance of the dNLR (2.2) in a population-based cohort of metastatic colorectal cancer patients treated with oxaliplatin-based first-line therapy
Authors: M. Pérez Martelo, J. Álvarez Fernández, I. Abdulkader Nallib, E. Brozos Vázquez, F. Vázquez Rivera, Y. Vidal Ínsua, S. Candamio Folgar, R. López López, J. Ruiz Bañobre
Journal: Annals of Oncology (2020)
P-181 Role of detection and quantification of plasma ctDNA RAS mutations by BEAMing digital PCR in patients with locally advanced and metastatic pancreatic cancer
Authors: S. Gkoura, M. Kastrisiou, A. Kougioumtzi, C. Tzallas, K. Gkrepi, A. Goussia, A. Christopoulou, A. Magklara, G. Pentheroudakis
Journal: Annals of Oncology (2020)
Baloxavir for Postexposure Prophylaxis against Influenza in Households
Authors: Timothy M. Uyeki
Journal: New England Journal of Medicine (2020)

In the United States, antiviral treatment of influenza is recommended as soon as possible in hospitalized patients and in outpatients who are at increased risk for influenza complications or have progressive disease, and it can be considered in non–high-risk patients presenting within 2 days after the onset of illness (early treatment).1,2 The neuraminidase inhibitors oseltamivir, zanamivir, and peramivir have been approved by the Food and Drug Administration (FDA) for the early treatment of uncomplicated influenza. Oseltamivir is recommended for the treatment of influenza in hospitalized patients.1 Neuraminidase inhibitors block the influenza viral surface protein neuraminidase to inhibit release of progeny . . .
A hitchhiker’s guide to working with large, open-source neuroimaging datasets
Authors: Corey Horien, Stephanie Noble, Abigail S. Greene, Kangjoo Lee, Daniel S. Barron, Siyuan Gao, David O’Connor, Mehraveh Salehi, Javid Dadashkarimi, Xilin Shen, Evelyn M. R. Lake, R. Todd Constable, Dustin Scheinost
Journal: Nature Human Behaviour (2020)
P-275 Quality of life and symptoms in patients undergoing CRS-HIPEC with or without perioperative systemic treatment for colorectal peritoneal metastases: Results from the randomised CAIRO6 trial
Authors: C. Bakkers, K. Rovers, A. Rijken, F. Mols, G. Simkens, A. Brandt-Kerkhof, J. Tuynman, A. Aalbers, N. Kok, M. Wiezer, P. de Reuver, W. van Grevenstein, P. Hemmer, M. Dijkgraaf, C. Punt, P. Tanis, I. de Hingh
Journal: Annals of Oncology (2020)
Obesity is a potential risk factor for covid-19 associated morbidity and mortality in urban Bangladesh
Authors: Syed Imran Ahmed, S M Tafsir Hasan, Tahmeed Ahmed
Journal: BMJ (2020)

Tan and colleagues investigate the link between obesity and covid-19.1

Rates of overweight and obesity—a pre-eminent public health problem of the modern world—are growing in Bangladesh,2 and are probably an underlying factor in the high rate of covid-19 associated morbidity and mortality in the country. By 19 June, 90 619 covid-19 cases have been identified,3 mostly concentrated in urban areas.4 …
P-309 Correlation between baseline CEA levels and TNM stage at presentation in colorectal cancers in an Indian population
Authors: V. Koyyala, A. Jajodia, A. Gupta, A. BP, A. Chaturvedhi, A. Rao, A. Mehta, N. Gupta, S. Pasricha, S. Joga, P. Medisetty, M. La Mantia, S. Goyal, S. Singh
Journal: Annals of Oncology (2020)
Response to Letter Regarding Article, “Glucose-Insulin-Potassium Reduces the Incidence of Low Cardiac Output Episodes After Aortic Valve Replacement for Aortic Stenosis in Patients With Left Ventricular Hypertrophy: Results From the Hypertrophy, Insulin, Glucose, and Electrolytes (HINGE) Trial”
Authors: Neil J. Howell, David W. Quinn, David Green, Nigel E. Drury, Aaron M. Ranasinghe, Jorge Mascaro, Timothy R. Graham, Stephen J. Rooney, Ian C. Wilson, Domenico Pagano, Houman Ashrafian, Hussain Contractor, Henrik Isackson, Melanie Calvert, Lynne K. Williams, Michael Frenneaux, Robert S. Bonser, Nick Freemantle
Journal: Circulation (2011)
Treatment of Relapse of MDS, AML and CMML after Allogeneic Blood Stem Cell Transplantation with Azacitidine, Lenalidomide and Donor Lymphocyte Infusions - Results from the First Interim Analysis of the Azalena-Trial (NCT02472691)
Authors: Thomas Schroeder, Christina Rautenberg, Max Christopeit, Matthias Stelljes, Eva Schmidt, Stefan Klein, Christof Scheid, Dietrich W Beelen, Kathrin Nachtkamp, Rainer Haas, Ulrich Germing, Nicolaus Kröger, Guido Kobbe
Journal: Blood (2017)
P-225 KRAS codon 12 and 13 mutations in metastatic colorectal cancer: Predictive marker in first-line bevacizumab-based chemotherapy
Authors: T. Cunha Pereira, F. Salgueiro, A. Monteiro, R. Félix Soares, F. Macedo, P. Jacinto, J. Paulo, N. Bonito, M. Marques, J. Ribeiro, G. Sousa
Journal: Annals of Oncology (2020)
Nightingale’s year of nursing: rising to the challenges of the covid-19 era
Authors: David R Thompson, Philip Darbyshire
Journal: BMJ (2020)

WHO designated 2020 the year of nursing, little knowing that the pandemic would soon change health professions universally. The events offer an opportunity to reform a beleaguered profession as full of potential and passion as its founder, write <b>David R Thompson</b> and <b>Philip Darbyshire</b>
P-325 Oral delivery of a single microbial strain, EDP1503, induces anti-tumor responses via gut-mediated activation of both innate and adaptive immunity
Authors: D. McHale, L. Francisco-Anderson, P. Sandy, S. Shariffudin, M. Goldberg, H. Gardner, M. Abdou, S. Kashyap, S. Argueta, P. Parameswaran, C. Davitt, H. Ponichtera, M. Carlson, M. Sizova, V. Kravitz, E. Troy, S. Andrewes, M. Bodmer, J. Bendell, J. Wang, S. Ulahannan, M. Chisamore
Journal: Annals of Oncology (2020)
Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts
Authors: Hideyuki Ikematsu, Frederick G. Hayden, Keiko Kawaguchi, Masahiro Kinoshita, Menno D. de Jong, Nelson Lee, Satoru Takashima, Takeshi Noshi, Kenji Tsuchiya, Takeki Uehara
Journal: New England Journal of Medicine (2020)

Baloxavir marboxil (baloxavir) is a polymerase acidic protein (PA) endonuclease inhibitor with clinical efficacy in the treatment of uncomplicated influenza, including in outpatients at increased risk for complications. The postexposure prophylactic efficacy of baloxavir in the household setting is unclear.We conducted a multicenter, double-blind, randomized, placebo-controlled trial to evaluate the postexposure prophylactic efficacy of baloxavir in household contacts of index patients with confirmed influenza during the 2018-2019 season in Japan. The participants were assigned in a 1:1 ratio to receive either a single dose of baloxavir or placebo. The primary end point was clinical influenza, as confirmed by reverse-transcriptase-polymerase-chain-reaction testing, over a period of 10 days. The occurrence of baloxavir-selected PA substitutions associated with reduced susceptibility was assessed.A total of 752 household contacts of 545 index patients were randomly assigned to receive baloxavir or placebo. Among the index patients, 95.6% had influenza A virus infection, 73.6% were younger than 12 years of age, and 52.7% received baloxavir. Among the participants who could be evaluated (374 in the baloxavir group and 375 in the placebo group), the percentage in whom clinical influenza developed was significantly lower in the baloxavir group than in the placebo group (1.9% vs. 13.6%) (adjusted risk ratio, 0.14; 95% confidence interval [CI], 0.06 to 0.30; P<0.001). Baloxavir was effective in high-risk, pediatric, and unvaccinated subgroups of participants. The risk of influenza infection, regardless of symptoms, was lower with baloxavir than with placebo (adjusted risk ratio, 0.43; 95% CI, 0.32 to 0.58). The incidence of adverse events was similar in the two groups (22.2% in the baloxavir group and 20.5% in the placebo group). In the baloxavir group, the viral PA substitutions I38T/M or E23K were detected in 10 (2.7%) and 5 (1.3%) participants, respectively. No transmission of these variants from baloxavir-treated index patients to participants in the placebo group was detected; however, several instances of transmission to participants in the baloxavir group could not be ruled out.Single-dose baloxavir showed significant postexposure prophylactic efficacy in preventing influenza in household contacts of patients with influenza. (Funded by Shionogi; Japan Primary Registries Network number, JapicCTI-184180.).
Evaluation of the proapoptotic and antiproliferative effects of the heterotrimeric G-protein complex inhibitor BIM46187 using multiplexed high content assays analyzed by automated flow cytometry
Authors: Gabriele Depierre, L. Schembri, F. De Giorgi, Tauhid Ali, Danièle Demarquay, Philip Kasprzyk, Helene Coulomb, Gregoire P. Prevost
Journal: Cancer Research (2006)

4718  Many G-protein coupled receptor agonists fuel the tumor progression. BIM-46187 is a new synthetic inhibitor of the heterotrimeric G-protein complex blocking the activation of G-protein dependent signaling pathways. In order to evaluate its antiproliferative activity and its ability to induce apoptosis, we have used a cellular clone derived from a human cervical carcinoma cell line (HeLa) engineered to stably express a recombinant biosensor reporting the activity of caspase 3 (C3) that is distinctive of apoptosis. The detection of C3 activity is multiplexed with proliferation and cell cycle detection using automated flow cytometry. BIM-46187 blocks cell proliferation and induces apoptosis in a concentration dependent manner. Furthermore, the longer is the treatment with BIM-46187 the lower are the EC50s. Interestingly, for all the treatment durations studied here, the EC50s observed for the inhibition of cell proliferation are between 3 and 15 times lower than the EC50s observed for C3 activation. In the presence of caspase inhibitors, the antiproliferative activity of BIM-46187 is still observed in these tumor cells. Altogether these data reinforce the interest to consider heterotrimeric G-protein as a new anticancer target.
Association of Hospital-Level Acute Resuscitation and Postresuscitation Survival With Overall Risk-Standardized Survival to Discharge for In-Hospital Cardiac Arrest
Authors: Saket Girotra, Brahmajee K. Nallamothu, Yuanyuan Tang, Paul S. Chan
Journal: JAMA Network Open (2020)

Survival after in-hospital cardiac arrest depends on 2 distinct phases: responsiveness and quality of the hospital code team (ie, acute resuscitation phase) and intensive and specialty care expertise (ie, postresuscitation phase). Understanding the association of these 2 phases with overall survival has implications for design of in-hospital cardiac arrest quality measures.To determine whether hospital-level rates of acute resuscitation survival and postresuscitation survival are associated with overall risk-standardized survival to discharge for in-hospital cardiac arrest.This observational cohort study included 86 426 patients with in-hospital cardiac arrest from January 1, 2015, through December 31, 2018, recruited from 290 hospitals participating in the Get With The Guidelines-Resuscitation registry.Risk-adjusted rates of acute resuscitation survival, defined as return of spontaneous circulation for at least 20 minutes, and postresuscitation survival, defined as survival to discharge among patients achieving return of spontaneous circulation.The primary outcome was overall risk-standardized survival rate (RSSR) for in-hospital cardiac arrest calculated using a previously validated model. The correlation between a hospital's overall RSSR and risk-adjusted rates of acute resuscitation and postresuscitation survival were examined.Of 86 426 patients with in-hospital cardiac arrest, the median age was 67.0 years (interquartile range [IQR], 56.0-76.0 years); 50 665 (58.6%) were men, and 71 811 (83.1%) had an initial nonshockable cardiac arrest rhythm. The median RSSR was 25.1% (IQR, 21.9%-27.7%). The median risk-adjusted acute resuscitation survival was 72.4% (IQR, 67.9%-76.9%), and risk-adjusted postresuscitation survival was 34.0% (IQR, 31.5%-37.7%). Although a hospital's RSSR was correlated with survival during both phases, the correlation with postresuscitation survival (ρ, 0.90; P < .001) was stronger compared with the correlation with acute resuscitation survival (ρ, 0.50; P < .001). Of note, there was no correlation between risk-adjusted acute resuscitation survival and postresuscitation survival (ρ, 0.09; P = .11). Compared with hospitals in the lowest RSSR quartile, hospitals in the highest RSSR quartile had higher rates of acute resuscitation survival (75.4% in quartile 4 vs 66.8% in quartile 1; P < .001) and postresuscitation survival (40.3% in quartile 4 vs 28.7% in quartile 1; P < .001), but the magnitude of difference was larger with postresuscitation survival.The findings suggest that hospitals that excel in overall in-hospital cardiac arrest survival, in general, excel in either acute resuscitation or postresuscitation care but not both; efforts to strengthen postresuscitation care may offer additional opportunities to improve in-hospital cardiac arrest survival.
LBA-7 Encorafenib plus cetuximab with or without binimetinib for BRAFV600E metastatic colorectal cancer (mCRC): Relationship between carcinoembryonic antigen (CEA) and clinical outcomes from BEACON CRC
Authors: A. Grothey, S. Kopetz, R. Yaeger, E. Van Cutsem, H. Wasan, J. Desai, F. Ciardiello, T. Yoshino, K. Maharry, J. Christy-Bittel, A. Gollerkeri, J. Tabernero
Journal: Annals of Oncology (2020)
Estimating the efficacy of symptom-based screening for COVID-19
Authors: Alison Callahan, Ethan Steinberg, Jason A. Fries, Saurabh Gombar, Birju Patel, Conor K. Corbin, Nigam H. Shah
Journal: npj Digital Medicine (2020)

There is substantial interest in using presenting symptoms to prioritize testing for COVID-19 and establish symptom-based surveillance. However, little is currently known about the specificity of COVID-19 symptoms. To assess the feasibility of symptom-based screening for COVID-19, we used data from tests for common respiratory viruses and SARS-CoV-2 in our health system to measure the ability to correctly classify virus test results based on presenting symptoms. Based on these results, symptom-based screening may not be an effective strategy to identify individuals who should be tested for SARS-CoV-2 infection or to obtain a leading indicator of new COVID-19 cases.
P-131 Ramucirumab and irinotecan in patients with previously treated gastroesophageal adenocarcinoma: Interim analysis of a phase II trial
Authors: H. Park, A. Sanjeevaiah, R. Suresh, R. Mehta, N. Trikalinos, N. Bagegni, O. Aranha, K. Pedersen, A. Nixon, R. Jin, J. Mills, R. Fields, M. Amin, K. Lim, B. Tan, P. Grierson, S. Jiang, M. del Rosario, A. Wang-Gillam, A. Lockhart
Journal: Annals of Oncology (2020)
Establishment and characterization of a line of transgenic mice harboring a lung specific human type II p53(175H) mutation
Authors: Li Gao, Wenrui Duan, Yang Zhang, Xin Wu, Gregory A. Otterson, Miguel A. Villalona-Calero
Journal: Cancer Research (2005)

1055  Lung cancer is one of the most deadly diseases worldwide and more than 50% of lung cancers contain p53 mutations. Mutant p53 can be classified into two major types, the type I (contact) mutation and type II (conformational) mutation. Important differences between these types have been established, including a higher oncogenic potential for the type II mutation, and the conservation of some wild type activity for type I. We previously established a line of lung specific SPC-p53(273H), a type I p53 mutant, which spontaneously developed lung adenocarcinomas at a median age of 13-15 months. To investigate the role of type II p53 mutant in lung tumorigenesis, a transgenic mouse model with a human mutant p53(175H, Arg to His at codon 175, a type II mutant) was developed. The transgene was placed under the control of the human surfactant protein C (SPC) promoter to selectively express the mutant gene in lung tissue. Transgenic mice were generated by microinjection of a 6.7-kb fragment of the SPC-p53 construct into the pro-nuclei of FVB/N mouse zygotes. Four transgenic founders were identified; 3 females and 1 male. Two female mice did not pass the transgene, whereas the other two passed the transgene to the F1 generation, permitting to establish a line of SPC-p53(175H) transgenic mice. The ratio of transgenic to non-transgenic offspring was 38% (N=157). Expression of the human mutant p53(175H) in lung tissue was evaluated by immunohistochemistry and Western blot analysis using the human specific p53 antibody (DO-7). These analyses showed a high level of human p53 protein in the transgenic lung tissues. The mutant protein was found primarily in the nuclei of pneumocytes from the transgenic mice, and absent in lung tissue from non-transgenic littermates. The male founder developed a lung tumor (12 mm in diameter), identified pathologically as an adenocarcinoma, at necropsy at the age of 12 months. One of the F1 males also developed a lung adenocarcinoma (11mm in diameter) at the age of five months. The remaining mice will be evaluated for the rate of tumor formation at age intervals of 7-9, 10-12 and 13-15 months and compared to the incidence in non-transgenic littermates and type I mutants. The animal models discussed above should provide valuable information on the role of mutant p53 type in lung carcinogenesis and may provide a framework to further evaluate environmental carcinogens and the effects of these mutations on response to treatment interventions.
Serum Half-Lives for Short- and Long-Chain Perfluoroalkyl Acids after Ceasing Exposure from Drinking Water Contaminated by Firefighting Foam
Authors: Yiyi Xu, Tony Fletcher, Daniela Pineda, Christian H. Lindh, Carina Nilsson, Anders Glynn, Carolina Vogs, Karin Norström, Karl Lilja, Kristina Jakobsson, Ying Li
Journal: Environmental Health Perspectives (2020)

BACKGROUND: Firefighting foam-contaminated ground water, which contains high levels of perfluoroalkyl substances (PFAS), is frequently found around airports.In 2018 it was detected that employees at a municipal airport in northern Sweden had been exposed to high levels of short-chain PFAS along with legacy PFAS (i.e., PFOA, PFHxS, and PFOS) through drinking water.OBJECTIVES: In this study, we aimed to describe the PFAS profile in drinking water and biological samples (paired serum and urine) and to estimate serum half-lives of the short-chain PFAS together with legacy PFAS.METHODS: Within 2 weeks after provision of clean water, blood sampling was performed in all 26 airport employees.Seventeen of them were then followed up monthly for 5 months.PFHxA, PFHpA, PFBS, PFPeS, and PFHpS together with legacy PFAS in water and biological samples were quantified using LC/MS/MS.Half-lives were estimated by assuming one compartment, first-order elimination kinetics.RESULTS: The proportions of PFHxA, PFHpA, and PFBS were higher in drinking water than in serum.The opposite was found for PFHxS and PFOS.The legacy PFAS accounted for about 50% of total PFAS in drinking water and 90% in serum.Urinary PFAS levels were very low compared with serum.PFBS showed the shortest half-life {average 44 d [95% confidence interval (CI): 37, 55 d]}, followed by PFHpA [62 d (95% CI: 51, 80 d)].PFPeS and PFHpS showed average half-lives as 0.63 and 1.46 y, respectively.Branched PFOS isomers had average half-lives ranging from 1.05 to 1.26 y for different isomers.PFOA, PFHxS, and linear PFOS isomers showed average half-lives of 1.77, 2.87, and 2.93 y, respectively.DISCUSSION: A general pattern of increasing half-lives with increasing chain length was observed.Branched PFOS isomers had shorter half-lives than linear PFOS isomers.
Salmonella : un " vieux " pathogène qui gêne encore
Authors: S O’Brien, H de Valk
Journal: Eurosurveillance (2003)

Les evenements du 11 septembre 2001 ont engendre le spectre du bioterrorisme et des moyens considerables ont ete depuis mobilises pour preparer l'impensable (1). Ce numero d'Eurosurveillance nous rappelle que certains pathogenes bien connus constituent encore des menaces pour la sante publique, et qu'ils sont parfois a tort consideres sous controle. Ainsi, depuis peu, l'incidence de la salmonellose a considerablement diminue au sein de l'Union europeenne, le nombre de cas declares a Enternet (2) passant du pic de 100 267 en 1997, a 73 006 en 2001 (I.S.T. Fisher - communication personnelle). Pourtant, les evenements recents et les articles publies dans ce numero illustrent les defis continuels de la lutte contre cette infection.
Response to Letters Regarding Article, “Optimal Medical Therapy With or Without Percutaneous Coronary Intervention to Reduce Ischemic Burden: Results From the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) Trial Nuclear Substudy”
Authors: Leslee J. Shaw, Emir Veledar, Daniel S. Berman, Sean W. Hayes, John Friedman, Piotr Slomka, Guido Germano, David J. Maron, G. B. John Mancini, Pamela M. Hartigan, William S. Weintraub, Robert A. O'Rourke, Gary V. Heller, Marcin Dada, John A. Spertus, Benjamin McCallister, Bernard R. Chaitman, Gilbert Gosselin, Peter Berger, William J. Kostuk, Ronald G. Schwartz, Merill Knudtson, Eric R. Bates, Koon K. Teo, William E. Boden
Journal: Circulation (2008)
Sixty seconds on . . . reorganising the NHS
Authors: Gareth Iacobucci
Journal: BMJ (2020)

No, that was the last reorganisation. And, as it turned out so well, the government is apparently considering another one.

If reports in the Guardian 1 are accurate, the prime minister Boris Johnson has set up a taskforce to draw up plans for how the government might regain some control over NHS England that was relinquished in 2012 under the then health secretary Andrew Lansley’s controversial Health and …
Atherosclerotic Risk and Statin Use Among Patients With Peripheral Artery Disease
Authors: Lisandro D. Colantonio, Demetria Hubbard, Keri L. Monda, Katherine E. Mues, Lei Huang, Yuling Dai, Elizabeth A. Jackson, Todd M. Brown, Robert S. Rosenson, Mark Woodward, Paul Muntner, Michael E. Farkouh
Journal: Journal of the American College of Cardiology (2020)
P-161 Efficacy of third-line anti-EGFR-based treatment versus regorafenib/TAS-102 (R/T) according to primary tumor site in RAS/BRAF wild-type metastatic colorectal cancer patients
Authors: R. Vivolo, E. Bria, I. Zurlo, M. Bensi, E. Dell'Aquila, A. Anghelone, D. Corsi, G. Caira, D. Santini, D. Ingrosso, A. Emiliani, M. Calegari, F. Citarella, C. Pozzo, R. Grande, M. Basso, G. Tortora, L. Salvatore
Journal: Annals of Oncology (2020)
Angiosarcoma heterogeneity and potential therapeutic vulnerability to immune checkpoint blockade: insights from genomic sequencing
Authors: Amélie Boichard, Michael J. Wagner, Razelle Kurzrock
Journal: Genome Medicine (2020)

Abstract Background Angiosarcoma is an aggressive tumor. Recent case series describe exceptional responses to checkpoint blockade in this disease. Methods Herein, we explored the genomic correlates of 48 angiosarcomas from the Angiosarcoma Project (12,499 variants analyzed in 6603 genes; whole-exome sequencing) versus 10,106 pan-cancer tumors in The Cancer Genome Atlas including 235 sarcomas but no angiosarcoma. Results At the molecular level, angiosarcomas were heterogeneous. Those located in the face and scalp presented high tumor mutation burden, missense amino acid variations biased towards more hydrophobic (and therefore more immunogenic) peptides, and ultra-violet mutational signature. Conclusions Angiosarcoma molecular features are similar to those observed in melanoma and other skin tumors and may explain comparable immunotherapy sensitivity of these tumor types.
P-30 Survival benefit of surgical resection after first-line triplet chemotherapy and bevacizumab in patients with initially unresectable metastatic colorectal cancer
Authors: M. Elshenawy, A. Badran, A. Al Jubran, A. Alzahrani, M. Rauf, A. Eldali, S. Bazarbashi
Journal: Annals of Oncology (2020)